Walden Biosciences

Walden Biosciences company information, Employees & Contact Information

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Company Details

Employees
21
Founded
-
Address
One Kendall Square,
Email
in****@****ces.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Cambridge, MA
Looking for a particular Walden Biosciences employee's phone or email?

Walden Biosciences Questions

News

Walden Biosciences Announces Key Initiatives to Advance - GlobeNewswire

Walden Biosciences Announces Key Initiatives to Advance GlobeNewswire

Walden Biosciences launches with $51M and a 2-pronged approach to 'completely transform' kidney disease - Fierce Biotech

Walden Biosciences launches with $51M and a 2-pronged approach to 'completely transform' kidney disease Fierce Biotech

Member Spotlight: Q&A with Walden Biosciences - Massachusetts Biotechnology Council

Member Spotlight: Q&A with Walden Biosciences Massachusetts Biotechnology Council

Walden Biosciences teams up with Primula for kidney disease study - Pharmaceutical Technology

Walden Biosciences teams up with Primula for kidney disease study Pharmaceutical Technology

Walden Biosciences Announces Positive Topline Data from - GlobeNewswire

Walden Biosciences Announces Positive Topline Data from GlobeNewswire

Walden Biosciences to Fight Kidney Disease With $51 Million Series A - The Wall Street Journal

Walden Biosciences to Fight Kidney Disease With $51 Million Series A The Wall Street Journal

Walden Biosciences Announces First Subject Dosed in - GlobeNewswire

Walden Biosciences Announces First Subject Dosed in GlobeNewswire

Top Walden Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant